Navigation Links
Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
Date:2/11/2008

COPENHAGEN, Denmark, Feb. 11 /PRNewswire/ -- Santaris Pharma, the Danish biopharmaceutical company developing LNA based RNA medicines, announced today that Keith McCullagh, President and Chief Executive Officer, will be presenting an overview of the company and its goals for 2008 at the Biotechnology Industry Organisation's 10th Annual CEO & Investor Conference in New York, today, Monday February 11th at 12:30 pm, US Eastern Standard Time (18:30 Central European Time). The conference is being held at the Waldorf Astoria Hotel, New York City from February 11th-13th, 2008.

A live webcast of the Santaris Pharma presentation may be accessed from the news section of the company's website, http://www.santaris.com, where it will also be archived and available after the presentation.

About Santaris Pharma

Santaris Pharma is a Danish based clinical-stage biopharmaceutical company. The company was formed in 2003 and currently employs around 100 people. Santaris Pharma has the exclusive rights to LNA technology, a 3rd generation antisense chemistry used to develop new classes of RNA medicines, called RNA Antagonists and microRNA antagonists. Santaris Pharma's RNA Antagonists are targeted against tissue specific mRNAs associated with cancer, metabolic disorders and viral disease. In May 2006 Santaris Pharma completed a Euro 40m second round of equity financing and in December 2007 the Company completed a Euro 20m third round of equity financing. Santaris Pharma has a global partnership with Enzon Pharmaceuticals of New Jersey to co-develop and commercialise a series of Santaris Pharma RNA Antagonists for improving the treatment of cancer. GlaxoSmithKline has options to up to four Santaris Pharma drug candidates targeted against viral disease.

For further information please contact

Randi Krogsgaard, Director Corporate Communications

Direct phone: +45 45179879

Cell: +45
'/>"/>

SOURCE Santaris Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Calif. , Oct. 20, 2014 ... that the Company has signed a Notice of ... Regenerative Medicine (CIRM), effective October 1, 2014.  The ... Development payments and the release of additional grant ... CIRM grant award for clinical development of Asterias, ...
(Date:10/20/2014)... 20, 2014  GenVec, Inc. (NASDAQ: GNVC ) ... Ph.D., from its board of directors effective on October 24, ... and served as its chairman from June 2006 to November ... and Corporate Governance and Audit Committees of the board.  ... decade of dedicated service to GenVec, and its stockholders," said ...
(Date:10/20/2014)... Earle Martin , Chief ... that Ellen Teplitzky, an experienced attorney specializing in ... industry, has joined the firm as Director of ... practice. NDA Partners provides legal services, including ... to top law firms and their clients in ...
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... , ... Sinovac Biotech Ltd. ( SVA),a leading developer and provider ... (JV) agreement to establish Sinovac (Dalian) Vaccine,Technology Co., Ltd. ... human-use vaccines. Sinovac will contribute its expertise,and experience in ...
... This release is available in German . ... tags (Radio Frequency Identification) are increasingly finding their way into ... goods and identify them automatically by radio frequency. The appropriate ... label. Smart labels can be affixed to goods under production ...
... ... has agreed an AU$6.7 mil convertible note private placement with a U.S. institutional investor. ... advisor. , ... York (PRWEB) November 23, 2009 -- The independent New York investment bank KTA Capital, ...
Cached Biology Technology:Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Intelligence inside metal components 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2
(Date:10/15/2014)... non-traditional biophysics textbook and it describes how life functions ... discovery into biological systems and provides an understanding of ... about how our genes make proteins that control the ... in an organism. It quantifies the principles of life ... found on both large and small scales. The book ...
(Date:10/15/2014)... 44th Rosenstiel Award for Distinguished Work in Biomedical Science ... mechanisms of genomic instability and its implications for the ... alumnus to win the Rosenstiel Award; the first, Rod ... is the Charles A. Janeway Professor of Pediatrics and ... investigator at the Howard Hughes Medical Institute at Boston ...
(Date:10/14/2014)... have sequenced the house fly genome for the first ... from an insect that thrives in pathogen-rich dung piles ... in the journal Genome Biology , will increase ... how flies quickly adapt to resist insecticides, which could ... (Musca domestica) carry and transmit more than 100 human ...
Breaking Biology News(10 mins):New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2House fly genome reveals expanded immune system 2
... Stacia Sower, professor of biochemistry and director of ... University of New Hampshire, has received a $420,000 grant ... brain and pituitary hormones and receptors. With ... of NSF-funded research in the fields of hormonal genomics ...
... YORK (March 12, 2009) New software developed with ... researchers to rapidly identify individual animals by creating a ... The software, described in an issue of the journal ... origin of tigers from confiscated skins. The new software, ...
... (Mar. 12, 2009) Researchers from DaVinci Biosciences, Costa ... Ecuador, have determined that injecting a patient,s own bone ... column using multiple routes can be an effective treatment ... of life for SCI patients without serious adverse events. ...
Cached Biology News:Major NSF grant boosts UNH research on hormonal genomics 2Tracking tigers in 3-D 2Multiple route bone marrow stem cell injections show promise to treat spinal cord injury 2
... Supercoiled DNA Ladder is suitable ... 2 to 16 kb by ... bands can be visualized by ... also be detected on Southern ...
CREB-2 (H-290)...
... Dynabeads Tosylactivated (4.5 m). Hydrophobic naked ... coupling of antibodies for cell applications. Proteins ... covalent binding of primary amine groups (NH ... Coupling reactions can be performed at neutral ...
cysteine and glycine-rich protein 2,...
Biology Products: